Comparative Immunogenicity of Concomitant vs Sequential mRNA COVID-19 and Influenza Vaccinations
Public ClinicalTrials.gov record NCT06020118. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Randomized Study of the Immunogenicity and Duration of Antibody Response Against Circulating SARS-CoV-2 Variant and Influenza Viruses Following Concomitant Versus Sequential Administration of mRNA COVID-19 Vaccine and Quadrivalent Cell Culture-based Influenza Vaccine Among Children and Adults
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a prospective, randomized randomized immunologic study of response to influenza and SARS-CoV-2 vaccination across four of the US Influenza Vaccine Effectiveness (Flu VE) Network study sites.
Study identification
- NCT ID
- NCT06020118
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Enrollment
- 455 participants
Conditions and interventions
Interventions
- Simultaneous Vaccination (Influenza Vaccine and mRNA COVID booster) Biological
- Sequential Vaccination (Influenza vaccine then mRNA COVID booster) Biological
- Sequential Vaccination (mRNA COVID booster then Influenza vaccine) Biological
Biological
Eligibility (public fields only)
- Age range
- 6 Years to 64 Years
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 25, 2023 (Actual)
- Primary completion
- Mar 7, 2024 (Actual)
- Completion
- May 17, 2024 (Actual)
- Last update posted
- Jun 13, 2025
2023 – 2024
United States locations
- U.S. sites
- 8
- U.S. states
- 5
- U.S. cities
- 7
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Valleywise Health Comprehensive Health Center | Phoenix | Arizona | 85008 | — |
| ASU Biodesign Institute | Tempe | Arizona | 85281 | — |
| Centers for Disease Control and Prevention | Atlanta | Georgia | 30333 | — |
| Washington University IDCRU | St Louis | Missouri | 63110 | — |
| University Hospitals Cleveland Medical Center | Cleveland | Ohio | 44106 | — |
| VA Northeast Ohio Healthcare System (VANEOHS) | Cleveland | Ohio | 44106 | — |
| Senders Pediatrics | South Euclid | Ohio | 44121 | — |
| Department of Family Medicine, University of Pittsburgh School of Medicine | Pittsburgh | Pennsylvania | 15260 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06020118, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 13, 2025 · Synced Oct 28, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT06020118 live on ClinicalTrials.gov.